FIG. 2.

Proposed design for prospective, randomized phase 2 and phase 3 studies in WD. Given that currently there is no single endpoint describing all possible features of WD, we propose to develop a composite score (“severity score”) that includes and weights several clinical and laboratory parameters. Until then, a combination of changes of single parameters from baseline can be described as improved, unchanged, or worse.